Our objective is to further characterize the natural history of clinically localized prostate cancer managed conservatively. From standard prognostic factors, we will construct prognostic nomograms to compute for individual patients the probabilities of clinical progression (symptomatic local or distant) and of cancer-related death at a given time after diagnosis. Information from these """"""""conservative management"""""""" nomograms and our prior aggressive therapy nomograms will be used to construct more robust decision analysis models for men with clinically localized prostate cancer. Through a prospective clinical trial, we will test the hypothesis that men who choose treatment recommended by this model will be less likely to regret their decision. We will also use novel gene expression methods to identify and validate prognostically useful molecular markers that have the potential to increase the predictive accuracy of our nomograms.
Our Specific Aims are: 1) To further define the natural history of clinically localized prostate cancer by identifying in an epidemiologic, population-based study in the United Kingdom a consecutive cohort of 2000 men diagnosed with prostate cancer in the PSA era but managed conservatively. In collaboration with the Imperial Cancer Research Fund, we will identify from regional tumor registries 2000 men diagnosed between 1990 and 1996 who had no treatment for at least 6 months after diagnosis and are eligible for a minimum follow-up of 5 years (maximum 10-16 years by completion of the SPORE in 2006). We will identify a second cohort of 2000 men treated with hormonal therapy alone within 6 months of diagnosis. Diagnostic biopsy specimens (mostly TURP) and clinical information will be retrieved and uniformly graded and staged with centralized review and the data computerized for further analyses. 2) To derive a nomogram that predicts the probability of progression (to symptomatic local or distant metastases), based on clinical prognostic factors (clinical stage, Gleason grade, and PSA level) for those cohorts of men managed conservatively (untreated or with hormonal therapy alone). 3) To construct a decision-analysis model which incorporates information from the conservative management nomograms and the aggressive-therapy nomograms previously developed and determine in a prospective clinical trial whether patients who chose treatment identified by the model as most beneficial (in quality adjusted life years) are less likely to regret their choice. 4) To identify and validate expressed genes in prostate cancer that correlate with outcome and evaluate their ability to complement nomogram prediction of progression for clinically localized disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA092629-02S1
Application #
6664519
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-10
Project End
2003-08-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Van Calster, Ben; Wynants, Laure; Verbeek, Jan F M et al. (2018) Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. Eur Urol 74:796-804
Shoag, Jonathan; Liu, Deli; Blattner, Mirjam et al. (2018) SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest 128:381-386
Frånlund, Maria; Arnsrud Godtman, Rebecka; Carlsson, Sigrid V et al. (2018) Prostate cancer risk assessment in men with an initial P.S.A. below 3?ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial. Scand J Urol 52:256-262
Mikropoulos, Christos; Selkirk, Christina G Hutten; Saya, Sibel et al. (2018) Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer 118:266-276
Capogrosso, Paolo; Vertosick, Emily A; Benfante, Nicole E et al. (2018) Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade. Eur Urol :
Lee, Justin K; Sjoberg, Daniel D; Miller, Mariam Imnadze et al. (2018) Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients? Eur Urol 73:33-37
Autio, Karen A; Dreicer, Robert; Anderson, Justine et al. (2018) Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA Oncol 4:1344-1351
Heller, Glenn; McCormack, Robert; Kheoh, Thian et al. (2018) Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. J Clin Oncol 36:572-580
Abida, Wassim; Sawyers, Charles L (2018) Targeting DNA Repair in Prostate Cancer. J Clin Oncol 36:1017-1019
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457

Showing the most recent 10 out of 505 publications